

Abstract BOOK Nr	Abstract Title	Presenter	TOPIC
161	BURKITT'S LYMPHOMAS THAT ARISE SPONTANEOUSLY IN VK*MYC MICE SHARE SIMILAR MUTATIONS WITH THE HUMAN DISEASE AND ARE ACCELERATED BY DIVERSE SURVIVAL SIGNALS.	Dr Chesi Marta	Molecular Biology
162	PRO-ONCOGENIC FUNCTIONS OF HSP105 IN HUMAN B-CELL NON-HODGKIN LYMPHOMAS	Dr Di Nicola Massimo	Molecular Biology
163	DIMERIZATION AND MONOUBIQUITINATION OF THE PARACASPASE MALT1 ARE REQUIRED FOR THE SURVIVAL OF CELLS DERIVED FROM ABC DLBCL	Dr Thome Margot	Molecular Biology
164	BCL2 MUTATIONS IN B CELL LYMPHOMAS AND IN THE EVOLUTION OF FOLLICULAR LYMPHOMA	Dr Burkhard Regula	Molecular Biology
165	MYD88 L265P IN MARGINAL ZONE LYMPHOMAS.	Dr Martinez-Lopez Azahara	Molecular Biology
166	EBV-SPECIFIC MICRO-RNA VIA EXOSOME: A KEY INTER-CELLULAR MACHINERY BETWEEN EBV+ TUMOR AND TUMOR-SURROUNDING IMMUNE CELLS?	Dr Kotani Ai	Molecular Biology
167	RICHTER SYNDROME (RS) PROMOTER METHYLATION PATTERN DIFFERS FROM DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Dr Mensah Afua	Molecular Biology
168	THE GENOMIC LANDSCAPE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)	Dr Braggio Esteban	Molecular Biology
169	QUANTITATIVE ULTRA DEEP SEQUENCING TO CHARACTERIZE CLONAL EVOLUTION OF FOLLICULAR LYMPHOMA	Prof Richard Burack	Molecular Biology
170	GENOME-WIDE MAPPING OF TRANSCRIPTION FACTOR BINDING SITES IN ACTIVE CHROMATIN IDENTIFIES DEREGULATED IRF ACTIVITY AS MASTER REGULATOR OF HODGKIN LYMPHOMA-SPECIFIC GENE EXPRESSION	Dr Mathas Stephan	Molecular Biology
171	MULTIDIMENSIONAL SINGLE-CELL ANALYSIS OF BCR SIGNALING REVEALS PROXIMAL ACTIVATION DEFECT AS A HALLMARK OF CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS	Dr Palomba M. Lia	Molecular Biology
172	SELECTIVE QUANTIFICATION OF BMI-1 LEVELS IN THE NUCLEI OF FOLLICULAR LYMPHOMA CELLS SHOWS ITS ASSOCIATIONS WITH EZH2 GENE MUTATION AND REDUCED OVERALL SURVIVAL, INDEPENDENT OF FLIPI	Dr AlJohani Naif	Clinicopathological Correlations
173	MUM-1 IS A STRONG PROGNOSTIC IMMUNOHISTOCHEMICAL MARKER IN FOLLICULAR LYMPHOMA: COMPUTERIZED IMAGE ANALYSIS OF THE FL-2000 AND PRIMA RANDOMIZED GELA TRIALS.	Prof XERRI Luc	Clinicopathological Correlations
174	STRONG CD180 EXPRESSION : A NEW MARKER OF MARGINAL B-CELL LYMPHOMAS	Dr Baseggio Lucile	Clinicopathological Correlations
175	MULTIPARAMETER FLOW CYTOMETRY FOR IDENTIFICATION OF THE WALDENSTRÖM'S CLONE IN IGM-MGUS AND WALDENSTRÖM'S MACROGLOBULINEMIA: NEW CRITERIA FOR DIFFERENTIAL DIAGNOSIS AND RISK STRATIFICATION	Dr Paiva Bruno	Clinicopathological Correlations
176	CD70+ T CELLS ARE INDICATIVE OF TGF- β -MEDIATED IMMUNE SUPPRESSION AND PREDICT A POOR OUTCOME IN FOLLICULAR LYMPHOMA PATIENTS	Dr Yang Zhizhang	Clinicopathological Correlations
177	MYC TRANSLOCATION PARTNER GENE IS A PREDICTIVE FACTOR OF SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMAS IRRESPECTIVE OF SINGLE OR DOUBLE HIT MYC GENE ALTERATIONS: A LYSA STUDY	Dr Copie Bergman christiane	Clinicopathological Correlations
178	OVEREXPRESSION OF MYC, BCL2, MYC/BCL2, IGM, AS WELL AS NON-GERMINAL CENTRE B-CELL LIKE IMMUNOPHENOTYPE PREDICT A WORSE PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN A SERIES OF 670 DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS: A LYSA STUDY.	Dr Molina Thierry	Clinicopathological Correlations
179	CLINICAL RELEVANCE OF MYC, BCL2 AND BCL6 REARRANGEMENTS IN DIFFUSE LARGE B-CELL LYMPHOMA	Dr Caponetti Gabriel	Clinicopathological Correlations

180	PROGNOSTIC SIGNIFICANCE AND PHENOTYPIC MANIFESTATIONS OF MYC/BCL2 PROTEIN CO-EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH EXTRANODAL ORGAN INVOLVEMENT: A REPORT OF THE INTERNATIONAL DLBCL RITUXIMAB-CHOP CONSORTIUM PROGRAM STUDY	Dr Madadi Anusha	Clinicopathological Correlations
181	MICRORNAS OF THE MIR-17-92 CLUSTER PREDICT FOR OUTCOME IN R-CHOP-TREATED DIFFUSE LARGE B-CELL LYMPHOMA AND ARE SIGNIFICANTLY ASSOCIATED WITH EXPRESSION OF MYC PROTEIN	Dr Culpin Rachel	Clinicopathological Correlations
182	GENETIC ABNORMALITIES IN B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT LYMPHOMA (B-UCL): THE NEBRASKA EXPERIENCE	Dr Perry Anamarija	Clinicopathological Correlations
183	HOST IMMUNE GENE POLYMORPHISMS AND OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED BY IMMUNOCHEMOTHERAPY: RESULTS FROM A META-ANALYSIS BASED ON 1134 PATIENTS FROM TWO INDEPENDENT PROSPECTIVE COHORTS	Dr Ghesquieres Herve	Clinicopathological Correlations
184	CLINICOPATHOLOGIC AND HISTOLOGIC CHARACTERISTICS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: ANALYSIS OF 231 PATIENTS OF THE TENOMIC PROJECT FROM THE LYSA.	Dr Le Bras Fabien	Clinicopathological Correlations
185	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AT DIAGNOSIS IN PERIPHERAL T-CELL LYMPHOMA DISPLAY A DISTINCT CLINICAL PATTERN	Dr Clozel Thomas	Clinicopathological Correlations
186	PROGNOSTIC ROLE OF HISTOLOGICAL GRADE 3A IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. RESULTS OF AN F2-STUDY DATABASE	Dr Bellei Monica	Indolent Entities
187	PATTERNS OF CARE AND OUTCOMES OF FRONT-LINE CHEMOIMMUNOTHERAPY FOR ADVANCED STAGE, GRADE 3 (G3) FOLLICULAR LYMPHOMA (FL): DATA FROM THE NATIONAL LYMPHOCARE STUDY (NLCS)	Dr Nastoupil Loretta	Indolent Entities
188	VIROLOGIC RESPONSE IMPROVES PROGNOSIS IN PATIENTS WITH HEPATITIS C ASSOCIATED B-CELL NON-HODGKIN LYMPHOMAS, NATIONAL ANRS HC-13 LYMPHO-C STUDY RESULTS.	Dr Michot Jean Marie	Indolent Entities
189	INFLUENCE OF LIFESTYLE FACTORS ON THE EXPRESSION OF TUMOR-RELATED MICROENVIRONMENT T-CELLS AND THE IMPACT ON SURVIVAL IN FOLLICULAR LYMPHOMA (FL)	Dr Evens Andrew	Indolent Entities
190	COMPARISON OF CHOP V. CVP TREATMENT IN 835 UNITED STATES VETERANS WITH UNTREATED FOLLICULAR LYMPHOMA	Dr Carson Kenneth	Indolent Entities
191	A MULTICENTER PHASE II TRIAL OF BORTEZOMIB (B) COMBINED WITH RITUXIMAB (R) THERAPY FOR UNTREATED "HIGH TUMOR BURDEN" (HTB) INDOLENT NON-HODGKIN LYMPHOMA (NHL)	Dr Evens Andrew	Indolent Entities
192	FLUDARABINE-MITOXANTRONE-RITUXIMAB REGIMEN IN UNTREATED INTERMEDIATE/HIGH-RISK FOLLICULAR NON-HODGKIN	Dr Zinzani Pier Luigi	Indolent Entities
193	PROGNOSTIC ROLE OF BCL-2 MOLECULAR MONITORING IN PATIENTS WITH EARLY STAGE FOLLICULAR LYMPHOMA	Dr Pulsoni Alessandro	Indolent Entities
194	PHARMACOKINETICS (PK), SAFETY, AND OVERALL RESPONSE RATE (ORR) ACHIEVED WITH SUBCUTANEOUS (SC) RITUXIMAB (R) PLUS CHEMOTHERAPY (CT) WERE COMPARABLE TO THOSE WITH INTRAVENOUS (IV) ADMINISTRATION IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL): STAGE 1 RESULTS OF THE PHASE 3 SABRINA STUDY (BO22334)	Dr Davies Andrew	Indolent Entities

195	FINAL RESULTS OF THE BP22333 STUDY DEMONSTRATE NONINFERIOR PHARMACOKINETICS (PK) AND SAFETY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) RITUXIMAB AS MAINTENANCE THERAPY IN FOLLICULAR LYMPHOMA (FL)	Dr Salar Antonio	Indolent Entities
196	FCGR3A AND FCGR2A POLYMORPHISMS DO NOT PREDICT RESPONSE RATE OR DURATION IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH SINGLE-AGENT RITUXIMAB: A PROSPECTIVE CORRELATIVE ANALYSIS FROM THE RESORT STUDY (ECOG E4402).	Dr Kahl Brad	Indolent Entities
197	SIGNIFICANCE OF THE QUANTITATIVE BCL2/IGH@ REARRANGEMENT EVALUATION IN PATIENTS AFFECTED BY FOLLICULAR LYMPHOMA AFTER CONVENTIONAL TREATMENT: THE ANCILLARY STUDY OF THE FIL-FOLL05 TRIAL.	Dr Galimberti Sara	Indolent Entities
198	MINIMAL RESIDUAL DISEASE (MRD) AT MULTIPLE TIMEPOINTS IS A STRONG OUTCOME PREDICTOR IN FOLLICULAR LYMPHOMA (FL) PATIENTS: RESULTS OF THE ML17638 TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL)	Dr Ladetto Marco	Indolent Entities
199	THE USE OF RITUXIMAB AT FIRST-LINE DOES NOT IMPAIR THE EFFICACY OF SECOND-LINE THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA. RESULTS OF THE REFOLL STUDY BY THE FONDAZIONE ITALIANA LINFOMI (FIL).	Dr Rossi Giuseppe	Indolent Entities
200	A SINGLE CENTER PHASE II TRIAL OF 90YTTRIUM-IBRITUMOMAB-TIUXETAN PRODUCES HIGH RESPONSE RATES AS FIRST-LINE THERAPY FOR EARLY STAGE B CELL INDOLENT LYMPHOMA, INCLUDING BULKY DISEASE.	Dr Samaniego Felipe	Indolent Entities
201	TREATMENT OF FOLLICULAR LYMPHOMA WITH RADIOIMMUNOTHERAPY – DATA FROM THE RADIOIMMUNOTHERAPY NETWORK, AN INTERNATIONAL DATA BASE ON DAILY CLINICAL PRACTICE	Dr Scholz Christian	Indolent Entities
202	UPFRONT AUTOLOGOUS STEM-CELL TRANSPLANTATION IN TRANSFORMED INDOLENT NON-HODGKINS LYMPHOMA: AN OUTCOME-ANALYSIS	Dr Madsen Charlotte	Indolent Entities
203	A POINT SCORE SIMPLIFICATION FOR PRACTICAL USE OF THE RISK STRATIFICATION FOR SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) BASED ON HEMOGLOBIN, PLATELET COUNT, HIGH LDH LEVEL AND EXTRAHILAR LYMPHADENOPATHY.	Dr Montalban Carlos	Indolent Entities
204	PERFORMANCE OF THE MONOCLONAL ASSAY FOR CIRCULATING FREE LIGHT CHAINS (FLC) IN AL AMYLOIDOSIS	Dr Palladini Giovanni	Indolent Entities
205	B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AMONG ISRAELIS AND PALESTINIANS: DIVERSE DISEASE PATTERNS AND RISK FACTORS IN POPULATIONS IN GEOGRAPHIC PROXIMITY	Dr Paltiel Ora	Aggressive B-cell lymphoma
206	EFFECT OF PLACE OF RESIDENCE AND CARE ON SURVIVAL OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	Dr Villa Diego	Aggressive B-cell lymphoma
207	AN ENHANCED INTERNATIONAL PROGNOSTIC INDEX (NCCN-IPI) FOR RISK STRATIFICATION OF DLBCL PATIENTS IN THE RITUXIMAB ERA: VALIDATION USING THE BRITISH COLUMBIA CANCER AGENCY (BCCA) DATABASE	Dr Zhou Zheng	Aggressive B-cell lymphoma
208	IMPACT OF GENDER, BODY MASS INDEX (BMI) AND BODY SURFACE AREA (BSA) ON OUTCOMES OF DLBCL PATIENTS TREATED WITH RITUXIMAB (R): ANALYSIS OF THE U.S. NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) DATABASE	Dr Zhou Zheng	Aggressive B-cell lymphoma
209	MALE SEX EVOLVES AS A SIGNIFICANT RISK FACTOR IN DLBCL TREATED WITH RITUXIMAB ONLY IN ELDERLY, BUT NOT IN YOUNG PATIENTS: CORRELATION WITH RITUXIMAB (R) PHARMACOKINETICS	Prof Pfreundschuh Michael	Aggressive B-cell lymphoma

210	BCL2 PROTEIN EXPRESSION COMBINED WITH EARLY FDG-PET RESPONSE ALLOWS IMPROVED STRATIFICATION OF DLBCL PATIENTS	Dr Copie-Bergman Christiane	Aggressive B-cell lymphoma
211	FCGR3A/FCGR2A POLYMORPHISMS AND PROGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH IMMUNOCHEMOTHERAPY: RESULTS FROM A META-ANALYSIS BASED ON 1134 PATIENTS FROM TWO INDEPENDENT PROSPECTIVE COHORTS	Dr Ghesquieres Herve	Aggressive B-cell lymphoma
212	R-CHOEP-14 IMPROVES OVERALL SURVIVAL IN YOUNG HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA COMPARED WITH R-CHOP-14. AN UPDATED ANALYSIS WITH 5 YEARS MEDIAN FOLLOW UP OF THE POPULATION-BASED INVESTIGATION FROM THE DANISH LYMPHOMA GROUP.	Dr Gang Anne	Aggressive B-cell lymphoma
213	COMBINATION OF LENALIDOMIDE WITH R-CHOP (R2CHOP) OVERCOMES NEGATIVE PROGNOSTIC IMPACT OF NON-GCB PHENOTYPE IN DLBCL – A PHASE 2 STUDY	Dr Nowakowski Grzegorz	Aggressive B-cell lymphoma
214	PHASE 2 STUDY OF RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE WITH BORTEZOMIB (VCR-CAP) OR VINCRISTINE (R-CHOP) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED NON-GERMINAL CENTER B-CELL-LIKE (GCB) DLBCL	Prof Offner Fritz	Aggressive B-cell lymphoma
215	RESULTS OF A PHASE 2 MULTICENTER STUDY OF THE ADDITION OF RITUXIMAB (R) TO CODOX-M/IVAC FOR UNTREATED BURKITT'S LYMPHOMA (BL): IMPACT OF PLASMA AND CEREBROSPINAL FLUID (CSF) R LEVELS	Dr Evens Andrew	Aggressive B-cell lymphoma
216	TUMOR EPSTEIN-BARR VIRUS (EBV) REPLICATION IS ASSOCIATED WITH EARLY-ONSET AND AGGRESSIVE BEHAVIOR OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)	Dr Rovira Sole Jordina	Aggressive B-cell lymphoma
217	EPSTEIN BARR VIRUS (EBV) PRIMO-INFECTIONS (PI) AND REACTIVATION (REA) TREATMENT AFTER HEART TRANSPLANTATION, IN PREVENTION OF POST-TRANSPLANTATION LYMPHOPROLIFERATION DISEASE (PTLD). RESULTS OF A MONOCENTRIC PROSPECTIVE STUDY ON 299 PATIENTS AND HISTORICAL COMPARISON WITH 820 PATIENTS	Dr choquet sylvain	Aggressive B-cell lymphoma
218	RISK-TAILORED CNS PROPHYLAXIS IN A MONOINSTITUTIONAL SERIES OF 194 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED IN THE RITUXIMAB ERA	Dr Ferreri Andres	Aggressive B-cell lymphoma
219	OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AFTER FAILURE TO SECOND-LINE CHEMOTHERAPY: ANALYSIS OF PATIENTS INCLUDED IN THE INTERNATIONAL CORAL STUDY	Prof Van Den Neste Eric	Aggressive B-cell lymphoma
220	INFLUENCE OF PRIOR RITUXIMAB ON THE RESULTS OF AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: A GELTAMO STUDY.	Mrs Redondo ALBA	Aggressive B-cell lymphoma
221	COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) IS AN ESSENTIAL TOOL TO SUPPORT TREATMENT DECISIONS IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). RESULTS OF A MULTICENTER STUDY BY THE FONDAZIONE ITALIANA LINFOMI (FIL)	Dr Tucci Alessandra	Aggressive B-cell lymphoma
222	ELDERLY IPI (EIPi) IN DLBCL PTS AGE > 60 Y TREATED WITH RCHOP: INTERNATIONAL VALIDATION STUDY USING DATA FROM RICOVER-60 (GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP) AND LNH 98-5 (GROUPE D'ETUDE DE LYMPHOME D'ADULTES)	Dr Advani Ranjana	Aggressive B-cell lymphoma
223	TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS IN AN ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA POPULATION IN THE UNITED STATES	Dr Hamlin Paul	Aggressive B-cell lymphoma

224	TREATMENT APPROACH AND CAUSE SPECIFIC SURVIVAL IN ELDERLY PATIENTS DIAGNOSED WITH DIFFUSE LARGE B-CELL LYMPHOMA.	Dr Dyszkiewicz-Korpany Anna	Aggressive B-cell lymphoma
225	PATIENT-REPORTED SYMPTOMS ARE STILL THE SINGLE MOST IMPORTANT FACTOR FOR DETECTING LYMPHOMA RELAPSE	Dr El-Galaly Tarec Christoffer	Aggressive B-cell lymphoma
226	ROLE OF POST-THERAPY SURVEILLANCE SCANS IN THE DETECTION OF DIFFUSE LARGE B-CELL LYMPHOMA RELAPSE: RESULTS OF TWO INDEPENDENT COHORTS	Dr Ghesquieres Herve	Aggressive B-cell lymphoma
227	IMMUNOGENETIC ANALYSIS OF THE B-CELL REPERTOIRE OF INDOLENT MCL WITH A SPLENIC PRESENTATION	Dr SARKOZY Clementine	Mantle Cell Lymphoma
228	SOX11 IS A TUMOR REGULATORY PROTEIN IN MANTLE CELL LYMPHOMA AND INCREASED EXPRESSION LEVELS CORRELATES TO OVERALL SURVIVAL IN A HOMOGENOUSLY TREATED COHORT	Ms Nordstr Lena	Mantle Cell Lymphoma
229	RESPONSE RATES USING STANDARD CRITERIA, FDG-PET AND MRD MEASUREMENT AFTER 4 COURSES OF R-DHAP AND AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA, RESULTS FROM THE LYMA TRIAL CONDUCTED ON BEHALF OF THE LYSA GROUP.	Prof Le Gouill steven	Mantle Cell Lymphoma
230	PREEMPTIVE IMMUNOTHERAPY WITH RITUXIMAB SIGNIFICANTLY PROLONGS THE DISEASE-FREE SURVIVAL IN PATIENTS WITH MOLECULAR RELAPSE OF MANTLE CELL LYMPHOMA	Dr Salek David	Mantle Cell Lymphoma
231	ZEVALIN (YTTRIUM-90 IBRITUMOMAB TIUXETAN) AND BEAM (Z-BEAM) VERSUS RITUXIMAB AND BEAM (R-BEAM) CONDITIONING CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MANTLE CELL LYMPHOMA.	Dr Berger Martin	Mantle Cell Lymphoma
232	PROTEOMIC ANALYSIS IDENTIFIES OUTCOME-PREDICTIVE MARKERS IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED.	Ms Ludvigsen Maja	T-cell Lymphoma
233	T-LGL LEUKEMIA AND NK-CHRONIC LYMPHOPROLIFERATIVE DISORDER: TWO DISEASES WITH A COMMON ETIOPATHOGENETIC MECHANISM?	Dr Zambello Renato	T-cell Lymphoma
234	HOW MANY PERIPHERAL T-CELL LYMPHOMAS ARE ELIGIBLE FOR AND ENTERED INTO CLINICAL TRIALS? A POPULATION-BASED ANALYSIS FROM THE DANISH LYMPHOMA REGISTRY	Dr Pedersen Martin	T-cell Lymphoma
235	LONG-TERM FOLLOW-UP OF THE PHASE II STUDY OF SMILE CHEMOTHERAPY FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE IV, RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE: THE NK-CELL TUMOR STUDY GROUP (NKTS) STUDY	Dr Suzuki Ritsuro	T-cell Lymphoma
236	THE EFFICACY AND SAFETY OF THE L-ASPARAGINASE-BASED REGIMEN (CHOP-L) IN COMBINATION WITH RADIOTHERAPY IN NEWLY DIAGNOSED EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE: A PROSPECTIVE PHASE II STUDY	Dr Lin Ningjing	T-cell Lymphoma
237	ALLOGENEIC-STEM CELL TRANSPLANTATION UPFRONT IN THE TREATMENT OF PATIENTS WITH ADVANCED T-CELL LYMPHOMA: AN INTENTION-TO-TREAT ANALYSIS FROM A SINGLE INSTITUTION.	Prof Le Gouill Steven	T-cell Lymphoma
238	LATE RELAPSES IN PERIPHERAL T-CELL LYMPHOMA PATIENTS TREATED IN THE NORDIC NLG-T-01 TRIAL	Prof D'Amore Francesco	T-cell Lymphoma
239	MANAGEMENT AND PROGNOSIS OF PATHOLOGICAL FRACTURES (PF) IN A SERIES OF 373 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF THE BONE (THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP – IELSG #14 STUDY)	Dr Govi Silvia	Extranodal Lymphoma
240	CONSTITUTIVELY ACTIVE STAT6 REPRESSES BCL6 IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL)	Dr Lennerz Jochen	Extranodal Lymphoma

241	HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION (JSHT)	Dr Kondo Eisei	Extranodal Lymphoma
242	INTENSIVE THERAPY OF THE PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA	Dr Mangasarova Jana	Extranodal Lymphoma
243	CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA IN GASTROINTESTINAL TRACT: RESULTS OF MULTICENTER RETROSPECTIVE ANALYSIS	Prof Kim Won Seog	Extranodal Lymphoma
244	MICRORNAS IN CEREBROSPINAL FLUID AS BIOMARKER FOR DISEASE COURSE MONITORING IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Dr Baraniskin Alexander	Extranodal Lymphoma
245	ONCOGENIC MICRORNAS IN CERBEROSPINAL FLUID AND SERUM: SENSITIVE TOOL FOR DETECTION OF CNS LYMPHOMA IN RESPONSE TO THERAPY	Dr Pospisil Vit	Extranodal Lymphoma
246	SIMILAR CHEMOKINE RECEPTOR PROFILES IN PCNSL AND SECONDARY CNS INVOLVEMENT OF SYSTEMIC DLBCL	Dr Pasanen Anna Kaisa	Extranodal Lymphoma
247	RITUXIMAB IN COMBINATION WITH METHOTREXATE-BASED CHEMOTHERAPY WITH BLOOD-BRAIN BARRIER DISRUPTION IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA	Dr Doolittle Nancy	Extranodal Lymphoma
248	METHOTREXATE, RITUXIMAB AND TEMOZOLOMIDE IN CNS LYMPHOMA: THE MAYO CLINIC EXPERIENCE	Dr Gupta Vinay	Extranodal Lymphoma
249	PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): A RETROSPECTIVE ANALYSIS OF DATA FROM THE DANISH LYMPHOMA REGISTRY LYFO	Dr Stoltenberg Danny	Extranodal Lymphoma
250	IELSG 34 – FINAL RESULTS OF A MULTICENTER PHASE II STUDY TO EVALUATE THE CLINICAL ACTIVITY AND THE SAFETY OF EVEROLIMUS IN MARGINAL ZONE B-CELL LYMPHOMAS (MZL)	Dr Conconi Annarita	Extranodal Lymphoma
251	A PHASE II TRIAL OF RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT-LYMPHOMA): AGMT (ARBEITSGEMEINSCHAFT MEDIKAMENTOESE TUMORTHERAPIE) MALT 2 STUDY	Dr Kiesewetter Barbara	Extranodal Lymphoma
252	SILENCER OF CYTOKINE SIGNALING 1 (SOCS1) GENE MUTATIONS IN CLASSICAL HODGKIN'S LYMPHOMA	Dr Lennerz Jochen	HL
253	RISK FACTORS AND STAGING SYSTEMS IN EARLY STAGE HODGKIN LYMPHOMA PATIENTS HAVE SIGNIFICANT IMPACT ON TREATMENT OUTCOME AFTER MODERN COMBINED MODALITY TREATMENT.	Prof Borchmann Peter	HL
254	DEEP INSPIRATION BREATH HOLD RADIATION THERAPY REDUCES RADIATION DOSE TO HEART IN PATIENTS TREATED FOR MEDIASTINAL HODGKIN LYMPHOMA	Dr Petersen Peter	HL
255	TAILORING THERAPY IN HODGKIN LYMPHOMA BASED ON PREDEFINED RISK FACTORS AND EARLY INTERIM PET/CT: ISRAELI H2 STUDY -PRELIMINARY REPORT ON 306 PATIENTS	Dr Dann Eldad	HL
256	PATTERNS OF FAILURE (POF) IN A RANDOMIZED PHASE III TRIAL OF ABVD VS. STANFORD V +/- RADIATION THERAPY (RT) IN LOCALLY EXTENSIVE AND ADVANCED STAGE HODGKIN'S LYMPHOMA (HL): AN INTERGROUP STUDY COORDINATED BY THE EASTERN COOPERATIVE ONCOLOGY GROUP (E2496)	Dr Wagner Henry	HL
257	PHARMACOGENETIC ANALYSIS OF CYP2B6 IN THE LRF CLL4 TRIAL: THE *6 ALLELIC VARIANT IS ASSOCIATED WITH INFERIOR EFFICACY FOLLOWING FLUDARABINE PLUS CYCLOPHOSPHAMIDE	Prof Pettitt Andrew	CLL
258	THE PROGNOSTIC IMPACT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA REQUIRING FIRST-LINE THERAPY	Dr Delgado Julio	CLL

259	A HIGH NUMBER OF LOSSES IN 11Q CHROMOSOME IS ASSOCIATED WITH SHORT TIME TO FIRST TREATMENT AND OVERALL SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. FINAL RESULTS OF DATABASE OF CLL OF SPANISH GROUP OF CYTOGENETICS (GCECGH) AND SPANISH GROUP OF CLL (GELLC)	Dr Hernandez Jose-Angel	CLL
260	FLUDARABINE, RITUXIMAB, AND LENALIDOMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Dr Flinn Ian	CLL
261	PLATINUM AND HIGH-DOSE CYTARABINE-BASED REGIMENS ARE EFFICIENT IN ULTRA HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA : RESULTS OF A RETROSPECTIVE MULTICENTER STUDY	Dr Durot Eric	CLL
262	CYTOKINE QUANTIFICATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH IBRUTINIB AND RITUXIMAB	Ms de Weerd Iris	CLL
263	BRAF INHIBITION IN HAIRY CELL LEUKEMIA	Dr Dietrich Sascha	CLL
264	EFFECT OF MOLECULAR SUBCLASS ON OUTCOMES AFTER RADIOIMMUNOTHERAPY-BASED AUTOLOGOUS STEM CELL TRANSPLANTATION IN DIFFUSE LARGE B-CELL LYMPHOMA	Dr Siddiqi Tanya	Transplantation
265	TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) WITH AGGRESSIVE INDUCTION CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) USING DENILEUKIN DIFTITOX (DD) FOR IN VIVO PURGING AND POST-TRANSPLANT THERAPY: PRELIMINARY RESULTS OF A PHASE II CLINICAL TRIAL.	Dr Kaplan Lawrence	Transplantation
266	AUTOLOGOUS AND ALLOGENEIC STEM-CELL TRANSPLANTATION FOR TRANSFORMED NON-FOLLICULAR INDOLENT LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP	Dr Villa Diego	Transplantation
267	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (CY) IS SAFE AND EFFECTIVE TO PREVENT IMMUNOLOGICAL REACTION AFTER UNMANIPULATED HAPLOIDENTICAL (HAPLO) TRANSPLANTATION FOLLOWING NONMYELOABLATIVE (NMA) CONDITIONING FOR ADVANCED LYMPHOMAS	Dr Castagna Luca	Transplantation
268	AUTOGRAFTING (ASCT) FOLLOWED BY REDUCED INTENSITY CONDITIONING REGIMEN (RICT) AS TREATMENT OF RESISTANT HODGKIN LYMPHOMA (HL). FOURTEEN YEARS OF EXPERIENCE.	Dr Carella Angelo Michele	Transplantation
269	BUSULFAN, MELPHALAN AND ETOPOSIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION ON PATIENTS WITH NON-HODGKIN'S LYMPHOMA: MULTICENTER STUDY FROM CONSORTIUM FOR IMPROVING SURVIVAL OF LYMPHOMA (CISL) IN KOREA	Dr Won Jong-Ho Won	Transplantation
270	BASELINE METABOLIC TUMOR VOLUME PREDICTS PATIENT'S OUTCOME IN HODGKIN LYMPHOMA	Mr Rossi Cedric	Imaging
271	FDG PET-CT AFTER FIRST-LINE TREATMENT PREDICTS PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL)	Dr GAINZA Eukene	Imaging
272	PROGNOSTIC VALUE OF 18FDG BASELINE FUNCTIONAL PET PARAMETERS IN PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA (PMLBCL)	Dr Ceriani Luca	Imaging
273	18F-FLUORODEOXYGLUCOSE (FDG) OUTPERFORMS 18F-FLUOROTHYIMIDINE (FLT) IN IDENTIFYING TRANSFORMATION OF FOLLICULAR LYMPHOMA, IN PARTICULAR THROUGH HETEROGENEITY IN UPTAKE	Dr Wondergem Marielle	Imaging
274	INTERIM PET SUVMAX REDUCTION IS SUPERIOR TO VISUAL ANALYSIS TO PREDICT PATIENT'S OUTCOME IN HODGKIN LYMPHOMA	Mr Rossi Cedric	Imaging

275	WHOLE-BODY DIFFUSION WEIGHTED MRI IN PATIENTS WITH DLBCL AND HODGKIN LYMPHOMA AT STAGING AND DURING TREATMENT	Dr Safar Violaine	Imaging
276	COMPARATIVE ASSESSMENT OF BONE MARROW INVOLVEMENT (BMI) BY BM BIOPSY (BMB) OR POSITRON EMISSION TOMOGRAPHY (PET) IN HODGKIN LYMPHOMA (HL)	Dr Vassilakopoulos Theodoros	Imaging
277	ONO-4059, A NOVEL ORAL BRUTON'S TYROSINE KINASE (BTK) INHIBITOR THAT DEMONSTRATES POTENT PHARMACODYNAMIC ACTIVITY THROUGH PHOSPHORYLATED BTK (P-BTK) INHIBITION, IN ADDITION TO EFFECTIVE ANTI-TUMOUR ACTIVITY IN A DLBCL XENOGRAFT MODEL	Dr Yoshizawa Toshio	New drugs - pre-clinical
278	GENOMIC INSTABILITY AND ACTIVATION OF THE DNA DAMAGE RESPONSE PATHWAY IS AN INDEPENDENT PREDICTOR OF POOR PROGNOSIS AND A PROMISING TARGET FOR THERAPY IN DIFFUSE LARGE B CELL LYMPHOMA	Dr Derenzini Enrico	New drugs - pre-clinical
279	TARGETING SIGNALING PATHWAYS IN MYCOSIS FUNGOIDES AND SEZARY SYNDROME	Dr Ai Wei	New drugs - pre-clinical
280	A NOVEL IRREVERSIBLE BTK INHIBITOR PLS-123 WITH ANTI-TUMOR ACTIVITY IN B-NHL PRECLINICAL MODELS	Dr Ding Ning	New drugs - pre-clinical
281	A NEW THERAPEUTIC APPROACH FOR THE THERAPY OF B-CELL DISORDERS: DRUG-LOADED ANTI-CD20 NANOPARTICLES	Dr Gabriele Pozzato	New drugs - pre-clinical
282	ALISERTIB (INVESTIGATIONAL AGENT) PLUS RITUXIMAB AND VINCRISTINE IS SYNTHETIC LETHAL IN MYC/BCL2 CO-EXPRESSING AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA MOUSE MODELS	Dr Mahadevan Daruka	New drugs - pre-clinical
283	DUAL TARGETING OF HISTONE DEACETYLASE AND NF-KAPPAB IN B- AND T-CELL LYMPHOMA	Dr Deng Changchun	New drugs - pre-clinical
284	DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA	Dr PEREZ-GALAN PATRICIA	New drugs - pre-clinical
285	EFFECTS OF RITUXIMAB AND GA-101 ON IN VITRO KILLING OF CELL LINES AND PATIENT LYMPHOMA CELLS BY NORMAL DONOR OR PATIENT EFFECTOR CELLS	Ms Wu Huei	New drugs - pre-clinical
286	SINGLE AND MULTIPLE DOSE-RANGING EVALUATION OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GS-9973, A NOVEL PSYK INHIBITOR	Dr Ramanathan Srin	New drugs - clinical
287	EXPLORATORY ANALYSIS OF THE RELATIONSHIP BETWEEN TARGET EXPRESSION AND EFFICACY OF ANTI-CD22-MMAE AND ANTI-CD79B-MMAE ANTIBODY DRUG CONJUGATES (ADC'S) IN PHASE I STUDIES	Dr Mundt Kirsten	New drugs - clinical
288	DENDRITIC CELL VACCINE FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF TRIAL LS1081	Dr Cordes Stefan	New drugs - clinical
289	A DOSE-FINDING STUDY OF BENDAMUSTINE, RITUXIMAB AND LENALIDOMIDE IN RELAPSED AND REFRACTORY LYMPHOMA	Prof Cheson Bruce	New drugs - clinical
290	PHASE I STUDY OF INOTUZUMAB OZOGAMICIN (INO) COMBINED WITH R-GDP FOR RELAPSED CD22+ B-CELL NON-HODGKIN LYMPHOMA (B-NHL)	Dr Sangha Randeep	New drugs - clinical
292	EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB (IR) IN HIGH-RISK CLL PATIENTS	Prof Burger Jan	New drugs - clinical
293	UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)	Dr Wang Michael	New drugs - clinical
294	PRELIMINARY SAFETY AND EFFICACY OF IPI-145, A POTENT INHIBITOR OF PHOSPHOINOSITIDE-3-KINASE- δ , γ , IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA	Dr Horwitz Steven	New drugs - clinical
295	FINAL REPORT OF A PHASE I STUDY OF IDELALISIB, A SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110 δ (PI3K δ), IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)	Dr Leonard John	New drugs - clinical

296	FINAL REPORT OF A PHASE I STUDY OF IDELALISIB, A SELECTIVE INHIBITOR OF PI3K δ , IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)	Dr Kahl Brad	New drugs - clinical
297	FINAL REPORT OF A PHASE I STUDY OF IDELALISIB (GS-1101) A SELECTIVE INHIBITOR OF PI3K δ , IN PATIENTS WITH RELAPSED OR REFRACTORY CLL	Dr Flinn Ian	New drugs - clinical
298	UPDATE ON A PHASE 1 STUDY OF THE SELECTIVE PI3K δ INHIBITOR, IDELALISIB (GS-1101) IN COMBINATION WITH RITUXIMAB (R), BENDAMUSTINE (B), OR BENDAMUSTINE/RITUXIMAB (BR) IN PATIENTS WITH RELAPSED OR REFRACTORY CLL	Dr Furman Richard	New drugs - clinical
299	PHASE II MULTICENTER STUDY OF LENALIDOMIDE IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA POST-BORTEZOMIB: MCL-001 "EMERGE" STUDY	Dr Goy Andre	New drugs - clinical
300	BCL-2 EXPRESSION AND CORRELATION WITH ACTIVITY IN A RANDOMIZED PHASE II STUDY OF NAVITOCCLAX (ABT-263) IN COMBINATION WITH RITUXIMAB (RTX) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Dr Punnoose Elizabeth	New drugs - clinical
301	WEEKLY MLN9708, AN INVESTIGATIONAL PROTEASOME INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA: PHASE 1 DOSE-ESCALATION STUDY	Dr Martin Peter	New drugs - clinical
302	FINAL RESULTS FROM A PHASE 1 STUDY OF BLINATUMOMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA (NHL)	Dr Goebeler Mariele	New drugs - clinical
303	PROGRESSION-FREE SURVIVAL ANALYSES OF TWO PIVOTAL PHASE 2 STUDIES OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA	Dr Radford John	New drugs - clinical
304	OBJECTIVE RESPONSES IN RELAPSED OR REFRACTORY B-CELL LYMPHOMAS WITH SINGLE-AGENT BRENTUXIMAB VEDOTIN	Dr Jacobsen Eric	New drugs - clinical
305	PROFILE OF PRETREATMENT PLASMA CYTOKINE LEVELS IN CHILDREN WITH ANAPLASTIC LARGE CELL LYMPHOMA	Dr Damm-Welk Christine	Pediatric Lymphoma
306	ARE MONOCLONAL ANTIBODY NECESSARY IN THE TREATMENT CHILDREN'S B-NON HODGKIN LYMPHOMA?	Prof Konja Josip	Pediatric Lymphoma
307	SURVEY OF TREATMENT RESULTS FOR PATIENTS WITH DLBCL IN POLISH PEDIATRIC LEUKEMIA/LYMPHOMA STUDY GROUP.	Dr Latos-Grazynska Elzbieta	Pediatric Lymphoma
308	OUTCOME AND TOXICITY PATTERNS IN CHILDREN WITH NON-HODGKIN'S LYMPHOMA	Dr Sheila Weitzman	Pediatric Lymphoma
309	MANAGEMENT OF PEDIATRIC HODGKIN LYMPHOMA IN CROATIA	Prof Konja Josip	Pediatric Lymphoma
310	RAPID EARLY RESPONSE TO HIGH-DOSE METHOTREXATE IN AN ADOLESCENT WITH MULTIFOCAL PRIMARY CNS LYMPHOMA	Dr Sheila Weitzman	Pediatric Lymphoma

